Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026

LOS ANGELES–(BUSINESS WIRE)–Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotechnology company, today announced that its first-in-class approach for treating hair loss with investigational medicine PP405 will be featured in a presentation about advances in the hair loss treatment landscape and regenerative mechanisms on Saturday, March 28th at the American Academy of Dermatology (AAD) Annual Meeting, taking place in Denver, Colorado. Presentation Details: Session: S020 New I
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks